The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2024 | Using MRD to guide post-alloSCT treatment decisions in AML
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the value of measurable residual disease (MRD) in guiding treatment decisions post-allogeneic stem cell transplantation (alloSCT) in acute myeloid leukemia (AML). The MORPHO (NCT02997202) and SORMAIN (EudraCT 2010-018539-16) trials provide evidence for the value of MRD in guiding post-alloSCT targeted therapy with gilteritinib and sorafenib, respectively. There are also ongoing trials investigating the role of MRD in guiding non-selective treatment decisions, such as azacitidine and venetoclax. Dr Thol also mentions the role of MRD in selecting the optimal donor for alloSCT, which is currently under investigation in the HaploMUD (NCT04232241) trial. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
